Patent ID: 8703726
Filing Date: 2014-04-22
Classification: A61K,A61P

Abstract:
1. A method for treating a prostate cancer or benign prostatic hyperplasia, comprising administering to a human having the prostate cancer or benign prostatic hyperplasia an effective amount of a compound of Formula (II): or a pharmaceutically acceptable salt, racemate or stereoisomer thereof, wherein, X is hydrogen; C R R wherein amino is optionally substituted with C wherein alkylamino and dialkylamino are each optionally substituted on alkyl with hydroxyl, C wherein morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, piperazinyl and oxiranyl are each optionally substituted with —C(O)—R R R R R wherein administering the compound to the human produces at least two of the results selected from the group consisting of: (i) decrease in the number of circulating tumor cells in the blood; (ii) increase in survival of the human; (iii) regression of the prostate cancer or benign prostatic hyperplasia; (iv) reduction in growth of the prostate cancer or benign prostatic hyperplasia; (v) inhibition or decrease in prostate-specific antigen levels in the range of about 30% to 100% relative to the prostate-specific antigen level prior to administration of the compound; (vi) decrease in tumor or benign prostatic hyperplasia metabolism or perfusion; (vii) stabilization or decrease in tumor or benign prostatic hyperplasia blood flow or metabolism; and (viii) stabilization or decrease in peritumoral or peri-benign prostatic hyperplasia inflammation or edema.